The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling the end of the programme ...

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by ...

On Wednesday, Morgan Stanley (NYSE:MS) downgraded Merck (NSE:PROR) KGaA (MRK:GR) (OTC: MKGAF) stock from Overweight to Equalweight and reduced its price target from EUR190.00 to EUR160.00.

Merck KGaA starts awareness push to help docs unravel form of MS, opening new front in Sanofi fight Blair first began speaking about her positive experience with Mavenclad last summer. In a video ...

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients. The ...

The Merck KGaA company collaborated with actress and patient advocate Selma Blair for the I Was Ready for Change campaign.